Waldenstroem macroglobulinemia · 6 regimens
Cost vs Efficacy · 4 points
| Regimen | Biomarker | Cost/cycle ↓ | Cycle | PFS ↕ | OS ↕ | Est. cycles | Course cost ↕ | Evidence |
|---|---|---|---|---|---|---|---|---|
Alemtuzumab monotherapy Variant #01 | — | R 132 218 | 7d | ~15.0 mo | — | ~66 | ~R 8 726 355 PFS proxy · indirect | — |
Bortezomib and Rituximab (VR) Variant #06 | — | R 64 235 | 35d | ~12.8 mo | — | ~12 | ~R 770 814 PFS proxy · indirect | 1 |
Cladribine and Rituximab Variant #01 | — | R 33 968 | 21d | — | — | — | — | — |
Bortezomib monotherapy Variant #14 | — | R 8 539 | 35d | ~30.3 mo | — | ~27 | ~R 230 565 PFS proxy · indirect | 5 |
Ofatumumab monotherapy N/A - secondary systemic drug | — | R 2 | 56d | ~8.1 mo | — | ~5 | ~R 9 PFS proxy · indirect | 4 |
Panobinostat monotherapy Variant #01 Partial | — | — | 21d | — | — | — | — | — |
6 of 6 regimens shown